The company has secured several partnerships for specific glaucoma drugs, has demonstrated in vitro release of therapeutic levels of drugs for over 90 days,
has shown efficacy in a 90 day Timolol animal study,
has shown that the device can be worn comfortably for several months nonstop and has had a meeting with the FDA to determine its regulatory path to the U.S. market.